Proteins and Peptides

09 Sep 2016 Emmaus Life Sciences Submits New Drug Application for Sickle Cell Disease Treatment
09 Sep 2016 Avelas Biosciences Completes Patient Enrollment for AVB-620 Phase 1b Clinical Trial
08 Sep 2016 La Jolla Pharmaceutical Company Reports Positive Results from Phase 1 Study of LJPC-401
07 Sep 2016 BioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease
01 Sep 2016 Long Acting Growth Hormone Based on Amunix' XTEN(R) Technology Completes Enrollment of Phase 3 Trial
31 Aug 2016 The Medicines Company Provides Update on Dyslipidemia Programs
30 Aug 2016 FDA Accepts CSL Behring's Biologics License Application for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks
30 Aug 2016 Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies
29 Aug 2016 ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia
27 Aug 2016 Adocia Announces Topline Results of Indian Phase 3 Trial of BioChaperone PDGF for Diabetic Foot Ulcer
23 Aug 2016 Hansa Medical: Top line results from the Swedish ongoing Phase II study with IdeS in sensitized patients presented
22 Aug 2016 Versartis Announces Completion of Enrollment in Phase 3 VELOCITY Trial of Somavaratan in Pediatric GHD
21 Aug 2016 Sanofi Provides Update on New Drug Application for Investigational Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
18 Aug 2016 Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa™ (andexanet alfa)
18 Aug 2016 JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women With Osteoporosis
18 Aug 2016 CollPlant Reports Positive Final Extended Clinical Trial Results with Vergenix™STR for Treatment of Tendinopathy
16 Aug 2016 Aurinia Pharmaceuticals announces voclosporin meets primary endpoint in phase IIb AURA-LV study in lupus nephritis
12 Aug 2016 Ascendis Pharma A/S Initiates Phase 3 Registration Trial for TransCon Growth Hormone in Children with Growth Hormone Deficiency
12 Aug 2016 Prometic completes patients' enrolment in pivotal plasminogen phase 2/3 clinical trial
12 Aug 2016 Phase II results with dasiglucagon (ZP4207) support its potential for use in a ready-to-use rescue pen to treat severe hypoglycemia in diabetes
10 Aug 2016 Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
10 Aug 2016 Cardiome Announces XYDALBA™ Single Dose Infusion Approval by European Medicines Agency
05 Aug 2016 Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine
01 Aug 2016 Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for Injection for the Treatment of Lower Limb Spasticity in Children Aged Two and Older
30 Jul 2016 First Patient Enrolled in Mallinckrodt Phase 3 Terlipressin Trial

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top